课题基金 / 基金详情

项目摘要

项目成果

G P CHROUSOS的其他基金

相似基金

相关文献

中文摘要
翻译
存在临床上有用的雌激素、雄激素和雌激素受体拮抗剂。 盐皮质激素糖皮质激素拮抗剂 已经发现了具有潜在临床用途的孕激素 最近本项目的目标是开发和研究 作用的分子机制和人的应用, 这两类类固醇的拮抗剂。我们测试了一个 开发了原型糖皮质激素-孕酮拮抗剂(RU 486) 最近,UCLAF。这种化合物对 人糖皮质激素和孕酮受体且不含激动剂 在小动物实验中的作用给非人灵长类动物或人的 RU 486导致血浆ACTH、皮质醇和精氨酸的长期升高 血管加压素,所有变化可通过先前施用 糖皮质激素(地塞米松)。这表明抗糖皮质激素 可用于激发下丘脑-垂体-肾上腺轴, 当需要在患有这种疾病的患者中进行临床试验时, 轴线重症库欣综合征的抗糖皮质激素治疗 由于异位ACTH分泌或肾上腺皮质肿瘤引起的综合征 缓解皮质醇增多症的临床表现。RU 486 增强了对标准刺激的炎症/免疫反应, 完整的动物,表明糖皮质激素发挥抗- 炎症/免疫抑制作用。我们 最近证明促肾上腺皮质激素释放激素(CRH)是 在炎症部位局部产生,并具有深刻的亲, 自分泌/旁分泌水平的炎症作用。我们称 这种“免疫”CRH糖皮质激素抑制,RU 486显著 增加炎症部位免疫CRH的局部分泌。免疫 CRH存在于卵巢和子宫内膜中,可能参与 排卵、黄体溶解和月经的炎症现象。 RU 486允许识别中枢神经系统缺陷, 容易患关节炎的老鼠在这些动物中, 应激介质不足以抑制免疫系统, 一种侮辱实际缺陷是全局的,位于 下丘脑CRH神经元,它对所有已知的CRH神经元的反应都很差, 兴奋剂,包括几种细胞因子,以及血清素, 乙酰胆碱和去甲肾上腺素。这种病理生理机制是 新的和它的相关性,人类关节炎和自身免疫性疾病将 接受检查。
英文摘要
Clinically useful antagonists exist for estrogens, androgens, and mineralocorticoids. Antagonists for the glucocorticoids or the progestins with potential clinical usefulness have been discovered recently. The objective of this project is to develop and study the molecular mechanisms of action and the human applications of the antagonists for both of these classes of steroids. We have tested a prototype glucocorticoid-progestin antagonist (RU 486) developed recently by Roussel-UCLAF. This compound has strong affinities for the human glucocorticoid and progestin receptor and is devoid of agonist effects in small experimental animals. Given to nonhuman primates or man RU 486 causes prolonged elevations of plasma ACTH, cortisol and arginine vasopressin, all changes preventable by previous administration of a glucocorticoid (dexamethasone). This suggests that antiglucocorticoids could be used for challenging the hypothalamic-pituitary-adrenal axis, when clinical testing is required in patients with disorders of this axis. Antiglucocorticoid therapy of patients with severe Cushing's syndrome due to ectopic ACTH secretion or adrenocortical tumors causes remission of the clinical manifestations of hypercortisolism. RU 486 potentiated the inflammatory/immune response to a standard stimulus in intact animals, suggesting that glucocorticoids exert anti- inflammatory/immunosuppressive effects at physiological levels. We recently demonstrated that corticotropin releasing hormone (CRH) is produced locally at the site of inflammation and has profound pro- inflammatory effects at an autocrine/paracrine level. We have called this "immune" CRH. Glucocorticoids suppress, and RU 486 markedly augments local secretions of immune CRH at an inflammatory site. Immune CRH was found in the ovary and endometrium where it may participate in the inflammatory phenomena of ovulation, luteolysis, and menstruation. RU 486 allowed the identification of a central nervous system defects in rats prone to arthritis. In these animals glucocorticoid response to stress-mediators is inadequate to restrain the immune system following an insult. The actual defect is global and located at the level of the hypothalamic CRH neuron, which responds poorly to all its known stimulants, including several cytokines, as well as serotonin, acetylcholine and norepinephrine. This pathophysiologic mechanism is novel and its relevance to human arthritis and autoimmune disease will be examined.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
PHYSIOLOGY AND PATHOPHYSIOLOGY OF THE HYPOTHALAMIC-PITUITARY-ADRENAL AXIS
PHYSIOLOGY OF STRESS AND CLINICAL APPLICATIONS OF CORTICOTROPIN RELEASING HORMONE
PHYSIOLOGY AND PATHOPHYSIOLOGY OF THE HYPOTHALAMIC-PITUITARY-ADRENAL AXIS
ENDOCRINE-IMMUNE INTERACTIONS
国内基金
海外基金
Autoimmune diseases therapies: variations on the microbiome in rheumatoid arthritis
Molecular Interaction Reconstruction of Rheumatoid Arthritis Therapies Using Clinical Data